Biological therapy in psychology is any treatment for mental health conditions that works by changing how the body and brain function physically, rather than through talk-based approaches. It includes psychiatric medications, brain stimulation techniques, and, in rare cases, surgical procedures. The core idea is straightforward: if mental health conditions involve measurable changes in brain chemistry or neural activity, then physical interventions can help correct those changes.
Most people encounter biological therapy in its most common form, prescription psychiatric medication. But the field has expanded significantly, and modern biological treatments now range from daily pills to magnetic pulses delivered to the scalp to small electrical devices implanted in the chest.
How Psychiatric Medications Work
Psychiatric medications are by far the most widely used biological therapy. They work by adjusting the levels or activity of chemical messengers in the brain called neurotransmitters. Different classes of medication target different messengers, which is why a drug prescribed for depression looks very different from one prescribed for psychosis.
The most commonly prescribed antidepressants, SSRIs, prevent serotonin from being reabsorbed after it’s released between brain cells. This keeps serotonin active in the brain longer, gradually raising its overall levels. A related class, SNRIs, does the same thing for both serotonin and norepinephrine, with a mild effect on dopamine as well. These medications typically take several weeks to produce their full effect, which reflects the slow process of rebalancing brain chemistry.
Anti-anxiety medications like benzodiazepines take a completely different approach. They bind to receptors for GABA, the brain’s main calming chemical, and amplify its effects. This produces faster relief than antidepressants, sometimes within minutes, but also carries a higher risk of dependence with long-term use.
Antipsychotic medications, used primarily for schizophrenia and bipolar disorder, target dopamine. First-generation antipsychotics block dopamine receptors directly. Second-generation (atypical) antipsychotics block both dopamine and serotonin receptors, which tends to produce fewer movement-related side effects but introduces a different set of risks. Between 15% and 50% of patients on atypical antipsychotics develop abnormal cholesterol levels, and these medications are also linked to weight gain, type 2 diabetes, and high blood pressure. These metabolic side effects are a major reason why an estimated 20% to 50% of patients with psychotic disorders eventually stop taking their medication.
Brain Stimulation Therapies
When medications don’t work well enough, or when side effects make them impractical, brain stimulation offers an alternative. These treatments deliver energy directly to specific brain regions to change neural activity patterns.
Electroconvulsive Therapy (ECT)
ECT is the oldest brain stimulation technique, with nearly 80 years of clinical use. It delivers brief electrical pulses to the brain under general anesthesia, triggering a controlled seizure that appears to reset certain neural circuits. Despite its difficult reputation, modern ECT looks nothing like its early history. Patients are sedated, given a muscle relaxant, and typically experience the procedure as falling asleep and waking up a short time later.
For treatment-resistant depression, ECT remains one of the most effective options available. In a major trial published in the New England Journal of Medicine, about 41% of patients with treatment-resistant depression responded to ECT. That number may sound modest, but these are patients for whom standard medications had already failed. The most common side effect is temporary memory disruption around the time of treatment, which usually resolves within weeks.
Transcranial Magnetic Stimulation (TMS)
TMS uses magnetic pulses, similar to those in an MRI machine, to stimulate nerve cells in targeted brain areas. Unlike ECT, it requires no anesthesia and no sedation. Patients sit in a chair while a device is positioned against the scalp, and sessions typically last 20 to 40 minutes.
The FDA first cleared TMS for major depression in 2008, specifically for adults who hadn’t responded adequately to antidepressant medication. Since then, approvals have expanded to include obsessive-compulsive disorder (2017), smoking cessation (2020), and depression with co-occurring anxiety symptoms. A standard course of TMS involves daily sessions over several weeks.
Vagus Nerve Stimulation (VNS)
VNS involves a small device surgically implanted under the skin of the chest, similar to a pacemaker, that sends regular electrical pulses to the brain through the vagus nerve. It’s reserved for severe, treatment-resistant depression. What makes VNS distinctive is that its benefits tend to accumulate over time. In a European study of 74 patients, response rates climbed from 37% at three months to 53% at a full year. Remission rates doubled over the same period, going from 17% to 33%.
A larger five-year study of 795 patients found even more striking long-term results. The group receiving VNS had a cumulative response rate of 67.6%, compared with 40.9% for patients receiving standard treatment alone. This slow-building effectiveness is unusual among psychiatric treatments and suggests VNS gradually reshapes brain activity patterns rather than producing an immediate chemical shift.
Newer Approaches: Ketamine and Deep Brain Stimulation
Ketamine represents a fundamentally different approach to treating depression. Rather than targeting serotonin or dopamine, it works on the glutamate system, the brain’s primary excitatory signaling network. Ketamine temporarily blocks certain receptors on inhibitory brain cells, which paradoxically leads to a burst of activity in excitatory cells, particularly in brain regions involved in mood regulation. The result is often rapid improvement in depressive symptoms, sometimes within hours, a timeline that no traditional antidepressant can match. In the same New England Journal of Medicine trial that tested ECT, 55.4% of patients responded to ketamine treatment.
Deep brain stimulation (DBS) sits at the most invasive end of the spectrum. Thin electrodes are surgically implanted into specific brain structures, delivering continuous electrical pulses to circuits involved in mood and behavior. For OCD, researchers have targeted several deep brain regions with varying success. For treatment-resistant depression, one promising target is a bundle of white matter fibers deep in the frontal lobe that connects regions involved in emotional processing. DBS remains largely experimental for psychiatric conditions, reserved for patients who have exhausted all other options.
Biological Therapy Combined With Psychotherapy
One of the most important findings in modern psychiatry is that biological therapy works best when paired with talk therapy. A meta-analysis examining long-term outcomes found that combining antidepressants with psychotherapy was nearly three times more effective than antidepressants alone at six months or longer. Interestingly, psychotherapy alone performed about as well as the combination in the long term, suggesting that therapy provides durable benefits that medication alone may not.
For maintenance treatment, the advantage of combination therapy held. Patients who continued both psychotherapy and medication after their initial improvement were significantly more likely to sustain their recovery than those on medication alone. This pattern reinforces the idea that biological therapy addresses the physical dimension of mental health conditions while psychotherapy builds the cognitive and behavioral skills that protect against relapse.
Genetic Testing and Personalized Treatment
One of the persistent challenges with psychiatric medication is that predicting who will respond to which drug has traditionally been a process of trial and error. Pharmacogenomic testing is changing this. A simple genetic test, usually a cheek swab, can reveal how your body metabolizes specific medications. People identified as “poor metabolizers” of a given drug are at higher risk for side effects because the medication builds up in their system faster than expected.
Beyond metabolism, genetic variants can also predict how well a medication will work at its target in the brain. Variations in the gene for the serotonin transporter, for example, have been shown to influence whether patients of European ancestry respond to SSRIs. This kind of testing doesn’t guarantee the right medication on the first try, but it narrows the field and can spare patients weeks of taking a drug that was unlikely to help them.